| DC8327 |
SANT-1
Featured
|
SANT-1 is a membrane permeable antagonist of the Shh (Sonic Hedgehog) signaling pathway by direct binding to Smo. |
|
| DC12276 |
Saridegib (IPI-926; Patidegib)
Featured
|
Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway. |
|
| DC4227 |
SB216763
Featured
|
SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3α with an IC50 value of 34 nM (similar potency for GSK3β). |
|
| DC7496 |
Semagacestat
Featured
|
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM. |
|
| DC10888 |
SKL2001
Featured
|
SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. |
|
| DC8391 |
Smoothened Agonist (SAG) HCl
Featured
|
Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells. |
|
| DC9782 |
SR-3029
Featured
|
SR 3029 is a potent and highly specific CK1δ/CK1ε inhibitor with the IC50 of 97 nM. |
|
| DC11791 |
SSTC3 |
SSTC3 is a novel small-molecule CK1α activator with EC50 of 30 nM (WNT-driven reporter gene assay), Kd of 32 nM. |
|
| DC9301 |
TA-01
Featured
|
TA-01 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction at 1 μM. Inhibits cardiomyocyte differentiation at 5 μM. Potently inhibits CK1ε, p38α, and CK1δ (IC50 values are 6.4, 6.7 and 6.8 nM respectively). |
|
| DC2067 |
TDZD-8
Featured
|
TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM. |
|
| DC7680 |
IM-12
Featured
|
The GSK3β Inhibitor XIX, IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling. |
|
| DC10472 |
Toxoflavin (PKF118-310)
Featured
|
Toxoflavin is an inhibitor of survivin expression and antagonist of Tcf4/b-catenin signaling |
|
| DC1063 |
TWS119
Featured
|
TWS119 is a GSK-3β inhibitor with IC50 of 30 nM. |
|
| DC4232 |
Vismodegib (GDC-0449)
Featured
|
Vismodegib (formerly GDC-0449) is a hedgehog antagonist, is also an orally bioavailable small molecule with potential antineoplastic activity. |
|
| DC11789 |
VU-WS113 |
VU-WS113 is a potent inhibitor of Wnt signaling with EC50 of 80 nM that selectively potentiates CK1α kinase activity.. |
|
| DC7744 |
WAY-262611
Featured
|
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate; with EC50 of 0.63 uM in TCF-Luciferase assay. |
|
| DC11132 |
Wnt-p53 inhibitor compound 2 |
Wnt-p53 inhibitor compound 2 is a novel inhibitor targets both Wnt signaling and ATM/p53, potently inhibits Wnt transcription (IC50=11 nM) and p53 transcription (EC50=1.9 nM). |
|
| DC11017 |
ZLDI-8
Featured
|
ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme ADAM-17, significantly decreases the level of NICD and accumulation of NICD in the nucleus; exhibits cytotoxic acitviity against MHCC97-H cells with IC50 of 5.32 uM, reduces the expression of pro-survival/anti-apoptosis regulators, Survivin and cIAP1/2, also increases the expression of epithelial marker E-Cadherin and reduces mesenchymal markers N-Cadherin and Vimentin in HCC cells; significantly disrupted the activity of Notch pathway in HCC cells and inhibits the epithelial-mesenchymal transition (EMT) process of HCC cells; ZLDI-8 treatment enhances the susceptibility of HCC cells to Sorafenib, Etoposide, and Paclitaxel both in vitro and in vivo. |
|
| DC7004 |
AR-A014418(GSK3β Inhibitor VIII)
Featured
|
AR-A014418 is a selective and effective GSK3β inhibitor with an IC 50 value of 104 +/- 27 nM; no significant inhibition on 26 other kinases. |
|
| DC7666 |
MK0752
Featured
|
MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2. |
|
| DC8225 |
Smoothened Agonist (SAG) free base
Featured
|
SAG is a potent Smoothened (Smo) receptor agonist (Kd = 59 nM); potently activates the Hedgehog signaling pathway in Shh-light 2 cells (EC50 ~ 3 nM). |
|
| DC9926 |
XMU-MP-1
Featured
|
XMU-MP-1 is a reversible and selective MST1/2 inhibitor with IC50 values of 71.1 ± 12.9 nM and 38.1 ± 6.9 nM against MST1 and MST2, respectively. |
|
| DC28074 |
gamma-secretase modulator 1 hydrochloride |
gamma-secretase inhibitior-1 is a gamma-secretase modulator, γ-secretase inhibitior-1 is useful for Alzheimer's disease. |
|
| DC28275 |
BIP-135 |
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect. |
|
| DC28365 |
(Rac)-BRD0705 |
(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML). |
|
| DC28675 |
Aβ42-IN-1 |
Aβ42-IN-1, compound 1v, is a novel, potent and orally active γ-secretase modulator (GSM). Aβ42-IN-1 potently reduced Aβ42 levels with an IC50 value of 0.091 µM without CYP3A4 inhibition. Aβ42-IN-1 shows a sustained pharmacokinetic profile. |
|
| DC28676 |
Aβ42-IN-1 free base |
Aβ42-IN-1 free base (compound 1v) is an orally active, high brain exposure γ-secretase modulator. Aβ42-IN-1 free base potently reduces Aβ42 levels with an IC50 value of 0.091 µM, and significantly reduces brain Aβ42 levels in mice. Aβ42-IN-1 free base is a promising compound for the treatment of Alzheimer’s disease. |
|
| DC28691 |
GSK-3β inhibitor 2 |
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease. |
|
| DC28717 |
CKI-7 |
CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases. |
|
| DC28730 |
N-Desmethylnefopam |
N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo. |
|
